Spektrum ochorení neuromyelitis optica // SOLEN

Neurológia pre prax 5/2019

The neuromyelitis optica spectrum disorders

The neuromyelitis optica spectrum disorders (NMOSD) includes neuromyelitis optica – NMO (characterized typically by optical neuritis and myelitis) and other particularly limited forms that include involvement of other parts of the CNS (brainstem, diencephalon, hypothalamus). NMOSD prevalence is low, but severe and rapid progressive disability in patients has led to extensive research in the field of diagnostics as well as therapeutic approaches in recent years. The discovery of specific serum immunoglobulin G antibodies selectively targeted to aquaporin 4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) have led to an understanding of different disease characteristics. In 2015 the currently valid diagnostic criteria for NMOSD were developed. The treatment is targeted to managing relapses and consequently preventing further events by immunosuppressants and monoclonal antibodies.

Keywords: spectrum neuromyelitis optica disorders, AQP4-IgG, MOG-IgG, eculizumab, satralizumab, inebilizumab